Tu Fu Ling (Smilax or Glabrous Greenbrier Rhizome)

Chinese Herb Actions

Chinese Herb Dosage

• What is the typical dosage of Tu Fu Ling?

  15–60 g — one of the largest standard dose ranges in the materia medica. The part used is the rhizome, sliced and dried. The high ceiling is a direct consequence of its nature: sweet, bland and neutral rather than bitter and cold, so it is tolerated at quantities that would be unthinkable for most toxicity-resolving herbs, and it is traditionally used in extended courses for chronic damp-heat patterns rather than in short bursts.

  • Form — sliced dried rhizome, decocted normally; no wrapping or special handling required. It is also used as a food-adjacent ingredient in southern Chinese soups.
  • Duration — suited to longer courses, which is unusual for its category; still a practitioner-directed herb, not a self-managed supplement.

  Source: our own herb record dosage range, cross-referenced against multiple online sources and published materia medica consensus. Reference only — not a prescription.

Chinese Herb Contraindications & Cautions

• Are there cautions for Tu Fu Ling?

  Tu Fu Ling is contraindicated in Liver and Kidney yin deficiency, and some traditional sources advise not taking it together with tea. Those are the two cautions on our own record. The yin-deficiency contraindication follows from its draining, damp-leaching action — it moves fluids out, which is the wrong direction where fluids are already depleted. The tea caution is a traditional dietary incompatibility repeated across the classical literature; the usual explanation given is that tea interferes with the herb’s action, and it is recorded here as a traditional instruction rather than a demonstrated pharmacological effect.

  • Liver and Kidney yin deficiency — contraindicated.
  • Tea — traditionally avoided during a course of this herb.
  • Large doses, long courses — because the standard range runs to 60 g and use is often sustained, this is a herb for practitioner-directed use, with the pattern reassessed over time.
  • Skin conditions and joint pain have many causes — traditional use assumes a qualified practitioner has established the damp-heat pattern.

  Source: our own herb record cautions, cross-referenced against multiple online sources and published materia medica consensus. Reference information, not medical advice.

Chinese Herb Toxicity & Overdose

• Low. Tu Fu Ling is regarded as a mild, well-tolerated herb — sweet, bland and neutral, given at 15–60 g and used in food preparations in southern China. It is not flagged as toxic or endangered on our own record, and no significant toxicity is reported at customary doses.

  Supporting laboratory context: astilbin, the herb’s principal flavanonol and its main quality marker, was assessed in a four-week oral toxicity study in rats at 50, 150 and 500 mg/kg/day alongside genotoxicity, chromosomal aberration and micronucleus testing. No adverse effects were observed and the no-observed-adverse-effect level was reported as greater than 500 mg/kg/day, with negative genotoxicity results. That is an isolated-compound animal study, not a clinical safety demonstration for the whole herb, but it is consistent with the traditional assessment of the material as gentle.

  Source: our own herb record; PMID 28624472, DOI 10.1016/j.fct.2017.06.024 (astilbin nonclinical toxicity, rats). Neutral reference note, not a safety guarantee.

Herb-Drug Interactions

• No well-established clinical herb–drug interactions are documented for Tu Fu Ling. Two points are worth practitioner awareness rather than concern. First, animal research repeatedly reports uric-acid-lowering activity for this rhizome, so anyone on urate-lowering medication should have both under one practitioner’s view — preclinical pharmacology, not a demonstrated clinical interaction. Second, the traditional instruction to avoid tea during a course of the herb is a dietary caution from the classical literature, recorded as tradition rather than as a documented pharmacokinetic effect. (Flagged for practitioner confirmation.)

Western / Biomedical Research

Chinese Herb Clinical Studies & Research

Provided as research context — a summary of published biomedical study, not a therapeutic or medical claim.

• Is there modern research on Tu Fu Ling (Smilacis Glabrae Rhizoma)?

  Yes — a well-developed preclinical literature built around the flavanonol astilbin, with animal evidence concentrated on uric acid, inflammation and skin, and no substantial human clinical trial evidence. A 2024 review in Heliyon summarises the chemistry: flavonoids, steroids, saccharides, phenolic glycosides, volatile constituents, organic acids, phenylpropanoids and stilbenoids, with astilbin, resveratrol and diosgenin proposed as quality markers.

  • Uric acid and gout models (animal) — rhizome extracts reduced serum uric acid, paw oedema, inflammatory cytokines and hepatic xanthine oxidase activity in mice given potassium oxonate and monosodium urate; separate work compared four astilbin stereoisomers in hyperuricaemic mice, and a serum-constituent study correlated absorbed compounds with urate reduction. Consistent across independent rodent studies — but rodent studies.
  • Inflammation and arthritis (preclinical) — astilbin attenuated inflammatory responses in complete Freund’s adjuvant-induced arthritis in rats, and reduced inflammatory signalling in lipopolysaccharide-stimulated macrophages.
  • Skin (animal) — total glucosides of the rhizome improved skin lesions in imiquimod-induced psoriasis-like mice and shifted the Th17/Treg ratio in affected tissue. This is the strand that lines up with the traditional damp-heat skin use, at a preclinical level only.
  • Metabolic and hepatic (animal) — astilbin alleviated high-fat-diet-induced metabolic dysfunction in mice, and mitigated acetaminophen-induced acute liver injury in mice via gut microbiota modulation.
  • Quality control — colorimetric and UPLC-Q-TOF-MS methods have been developed to assess Tu Fu Ling quality, and HPLC-MS comparison confirms it is chemically distinguishable from the related Smilacis Chinae Rhizoma — supporting authentication, not efficacy.

  Human clinical evidence is essentially absent; everything above is laboratory or animal work and none of it supports a treatment claim.

  Sources: PMID 38644901, PMC 11031832, DOI 10.1016/j.heliyon.2024.e29557 (review and quality markers); PMID 31005813, DOI 10.1016/j.phymed.2018.11.032 (hyperuricaemia/gout, mice); PMID 30851369 (astilbin stereoisomers, hyperuricaemic mice); PMID 24140588 (serum constituents and urate reduction); PMID 29104606 (astilbin in adjuvant arthritis, rats); PMID 25569518 (astilbin anti-inflammatory, macrophages); PMID 37611977 (total glucosides, psoriasis model); PMID 35388843 (astilbin, high-fat-diet metabolic dysfunction); PMID 39313515 (astilbin, acetaminophen liver injury, mice); PMID 27390588 (quality assessment by colorimetrics and UPLC-Q-TOF-MS); PMID 22400809 (chemical comparison with Smilacis Chinae Rhizoma). Research context, not a therapeutic claim.

Chinese Herb Notes

• Is Tu Fu Ling the same as Fu Ling, or as Western sarsaparilla?

  No to both — and both confusions are common. Tu Fu Ling is the rhizome of Smilax glabra Roxb., a climbing vine in the family Smilacaceae.

  • Fu Ling (茔茄) is Poria cocos — a fungus, not a plant, in a completely different category (herbs that drain dampness / promote urination) with a different flavour profile and different clinical role. The shared syllables are the only thing the two have in common. Tu (土, “earth”) in Tu Fu Ling marks it as the earthy, ground-growing look-alike, not a variety of Fu Ling.
  • Western sarsaparilla is also a Smilax, but a different species — tropical American plants such as Smilax ornata and Smilax regelii, whose root is the sarsaparilla of Western herbalism and old soft drinks. Same genus, different species, different continent, different traditional use and different chemistry. Tu Fu Ling is not sarsaparilla and the two should not be substituted.
  • Smilacis Chinae Rhizoma (Ba Qia, from Smilax china) is a separate Chinese medicinal from a related species; chemical comparison studies confirm the two rhizomes have distinguishable constituent profiles and are not interchangeable.

  What is the history of Tu Fu Ling as “China root” in Europe?

  Tu Fu Ling has a documented place in European medical history: in the 16th century it reached Europe as “China root” (radix Chinae) and was taken up as a remedy for syphilis. The anatomist Andreas Vesalius wrote a whole 1546 treatise on how to prepare and administer a decoction of it — the work known as the China Root Epistle — and China root sat alongside guaiacum and sarsaparilla in the European anti-syphilitic repertoire of the period. Nearly two centuries later Jean Astruc’s 1740 venereological treatise still catalogued Chinese plant medicines used against venereal disease, and a modern ethnopharmacological analysis of that text identifies Smilax glabra and Smilax china among them.

  This is history, not a therapeutic claim. The same modern analysis concludes that whatever effect those historical Chinese anti-syphilitic formulas had appears attributable to the mercury and arsenic compounds they contained rather than to the plant ingredients. Syphilis is a bacterial infection treated with antibiotics; nothing here suggests Tu Fu Ling treats it. The episode is recorded because it is a genuine and interesting piece of the herb’s documented past — and because it explains why older Western herbals list it at all.

  Note (for owner review): our own record gives the pharmaceutical Latin as “Rhizoma Smilacis Galbrae.” The standard form is Rhizoma Smilacis Glabrae (from Smilax glabra); “Galbrae” appears to be a transposition. The substance is unambiguous; the identity field is left unchanged pending owner confirmation.

  Source: PMID 27132716, DOI 10.1016/j.jep.2016.04.055 (analysis of Astruc’s 1740 venereological treatise, identifying Smilax glabra and S. china); PMID 28038492 (history-of-medicine article referencing Vesalius’s 1546 China Root Epistle); botanical distinctions per our own herb records and PMID 22400809. Historical context only.